POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone

Autor: MS Holleman, I Santi, S Huygens, KKH Aben, ACM Van den Bergh, AM Bergman, AJM van den Eertwegh, MCP Kuppen, J Lavalaye, NM Mehra, RJA van Moorselaar, IM Van Oort, DM Somford, HM Westgeest, WR Gerritsen, CA Uyl-De Groot

Publikováno v: Value in Health. 25:S266-S267

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b3846a39e27fe91586f32b70b4873acf
https://doi.org/10.1016/j.jval.2021.11.1300

Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study.

Autor: Beukema JC; Department of Radiation oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: j.c.beukema@umcg.nl., Haveman JW; Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Langendijk JA; Department of Radiation oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Oldehinkel E; Department of Radiation oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., van den Bergh ACM; Antoni van Leeuwenhoek Netherlands Cancer Institute, Amsterdam, the Netherlands., de Haan JJ; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., van Melle JP; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., van Luijk P; Department of Radiation oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Muijs CT; Department of Radiation oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Nov; Vol. 200, pp. 110479. Date of Electronic Publication: 2024 Aug 18.

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.

Autor: van den Bergh GPA; Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. vandenbergh@eshpm.eur.nl., Kuppen MCP; Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. kuppen@eshpm.eur.nl.; Department of Radiation Oncology, Maastro, Maastricht, The Netherlands. kuppen@eshpm.eur.nl., Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Aben KKH; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.; Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands., van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., van Moorselaar RJA; Department of Urology, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands., Somford DM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands., Bergman AM; Division of Internal Medicine (MOD) and Oncogenomics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van den Bergh ACM; Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands., Uyl-de Groot CA; Institute for Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2023 Mar; Vol. 26 (1), pp. 162-169. Date of Electronic Publication: 2022 Oct 12.

Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after Treatment.

Autor: Stelwagen J; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Meuleman AT; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Lubberts S; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Steursma G; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Kruyt LM; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Donkerbroek JW; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Meijer C; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Walenkamp AME; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Lefrandt JD; Department of Internal Medicine, Division of Vascular Medicine, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Rakers SE; Department of Neuropsychology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Huitema RB; Department of Neuropsychology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., de Jong MAA; Department of Radiotherapy, Radiotherapeutic Institute Friesland, 8900 CC Leeuwarden, The Netherlands., Wiegman EM; Department of Radiotherapy, Isala Hospital, 8025 AB Zwolle, The Netherlands., van den Bergh ACM; Department of Radiotherapy, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., de Jong IJ; Department of Urology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., van Rentergem JAA; Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, 1018 WV Amsterdam, The Netherlands., Schagen SB; Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, 1018 WV Amsterdam, The Netherlands., Nuver J; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands., Gietema JA; Department of Medical Oncology, University Medical Center Groningen and University of Groningen, 9728 NT Groningen, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2021 Nov 12; Vol. 13 (22). Date of Electronic Publication: 2021 Nov 12.

Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.

Autor: Bolla M; Radiotherapy Department Grenoble, Grenoble Alpes University, Centre Hospitalier Universitaire de Grenoble, Grenoble, France., Neven A; European Organization for Research and Treatment of Cancer, Brussels, Belgium., Maingon P; Sorbonne University, APHP Sorbonne University, La Pitié Salpêtrière, Paris, France., Carrie C; Radiotherapy Department, Leon Bérard Center, Lyon, France., Boladeras A; Radiation Oncology Department, Catalan Institute of Oncology-University Hospital Germans Trias I Pujol, Badalona, Barcelona, Catalonia, Spain., Andreopoulos D; Radiotherapy Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus., Engelen A; Institute Verbeeten, Tilburg, the Netherlands., Sundar S; Nottingham University Hospitals NHS Trust-City Hospital, Consultant Medical Oncologist, Nottingham, United Kingdom., van der Steen-Banasik EM; Radiotherapiegroep Arnhem, Arnhem, the Netherlands., Armstrong J; Radiation Oncology Department, All Ireland Cooperative Oncology Research Group, St Luke's Hospital, Dublin, Ireland., Peignaux-Casasnovas K; Radiotherapy Department, Georges-Francois-Leclerc Centre, Dijon, France., Boustani J; Radiotherapy Department, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France., Herrera FG; Radiation Oncology and Immuno-Oncology Service, University Hospital of Lausanne, Lausanne, Switzerland., Pieters BR; Department of Radiation Oncology, Amsterdam University Medical Centers/University of Amsterdam, Amsterdam, the Netherlands., Slot A; Radiotherapeutisch Instituut Friesland, Leeuwarden, the Netherlands., Bahl A; University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon, United Kingdom., Scrase CD; Ipswich Hospital National Health Services Trust, Ipswich, United Kingdom., Azria D; Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Montpellier, France., Jansa J; Klinika Onkologie a Radioterapie-Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic., O'Sullivan JM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Ireland., Van Den Bergh ACM; Radiotherapy Department, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Collette L; European Organization for Research and Treatment of Cancer, Brussels, Belgium.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Sep 20; Vol. 39 (27), pp. 3022-3033. Date of Electronic Publication: 2021 Jul 26.